MicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma

References

• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–1132. doi:10.1016/S0140-6736(09)60229-419269025
   PubMed Web of Science ®Google Scholar
• Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79–87. doi:10.14740/wjon127932494314
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Mytsyk Y, Dosenko V, Borys Y, et al. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma. Int Urol Nephrol. 2018;50(5):851–859. doi:10.1007/s11255-018-1841-x29549624
   PubMed Web of Science ®Google Scholar
• Aguiari G. MicroRNAs in clear cell renal cell carcinoma: biological functions and applications. J Kidney Cancer VHL. 2015;2(4):140–152. doi:10.15586/jkcvhl.2015.4028326269
   PubMedGoogle Scholar
• Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349(nov10 11):g4797. doi:10.1136/bmj.g479725385470
   PubMed Web of Science ®Google Scholar
• Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10(10):992–1000. doi:10.1016/S1470-2045(09)70240-219796751
   PubMed Web of Science ®Google Scholar
• Bedke J, Albiges L, Capitanio U, et al. The 2021 updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care. Eur Urol. 2021;80(4):393–397. doi:10.1016/j.eururo.2021.04.04234074559
   PubMed Web of Science ®Google Scholar
• Labriola MK, Batich KA, Zhu J, et al. Immunotherapy is changing first-line treatment of metastatic renal-cell carcinoma. Clin Genitourin Cancer. 2019;17(3):e513–e521. doi:10.1016/j.clgc.2019.01.01730858035
   PubMed Web of Science ®Google Scholar
• Crispen PL, Breau RH, Allmer C, et al. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol. 2011;59(1):18–23. doi:10.1016/j.eururo.2010.08.04220933322
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163(2):408–417. doi:10.1016/S0022-5347(05)67889-510647643
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233. doi:10.1016/j.cell.2009.01.00219167326
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257–2261. doi:10.1073/pnas.051056510316461460
   PubMed Web of Science ®Google Scholar
• Heinzelmann J, Henning B, Sanjmyatav J, et al. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol. 2011;29(3):367–373. doi:10.1007/s00345-010-0633-421229250
   PubMed Web of Science ®Google Scholar
• Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101(10):2087–2092. doi:10.1111/j.1349-7006.2010.01650.x20624164
   PubMed Web of Science ®Google Scholar
• Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42(8):1273–1281. doi:10.1016/j.biocel.2009.12.01420026422
   PubMed Web of Science ®Google Scholar
• Walmsley SR, McGovern NN, Whyte MK, et al. The HIF/VHL pathway: from oxygen sensing to innate immunity. Am J Respir Cell Mol Biol. 2008;38(3):251–255. doi:10.1165/rcmb.2007-0331TR17932373
   PubMed Web of Science ®Google Scholar
• Gu YZ, Moran SM, Hogenesch JB, et al. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 1998;7(3):205–213.9840812
   PubMed Web of Science ®Google Scholar
• Yu F, White SB, Zhao Q, et al. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer Res. 2001;61(10):4136–4142.11358837
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–472. doi:10.1126/science.105979611292861
   PubMed Web of Science ®Google Scholar
• Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464–468. doi:10.1126/science.105981711292862
   PubMed Web of Science ®Google Scholar
• Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther. 2010;10(7):658–664. doi:10.4161/cbt.10.7.1324720814228
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007;13(2 Pt 2):680s–684s. doi:10.1158/1078-0432.CCR-06-186517255293
   PubMed Web of Science ®Google Scholar
• Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol. 2010;7(5):277–288. doi:10.1038/nrclinonc.2010.4220368728
   PubMed Web of Science ®Google Scholar
• Huang WC, Swietach P, Vaughan-Jones RD, et al. Differentiation impairs low pH-induced Ca2+ signaling and ERK phosphorylation in granule precursor tumour cells. Cell Calcium. 2009;45(4):391–399. doi:10.1016/j.ceca.2009.01.00219249096
   PubMed Web of Science ®Google Scholar
• McCormick RI, Blick C, Ragoussis J, et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer. 2013;108(5):1133–1142. doi:10.1038/bjc.2013.5623449350
   PubMed Web of Science ®Google Scholar
• Fasanaro P, Greco S, Lorenzi M, et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem. 2009;284(50):35134–35143. doi:10.1074/jbc.M109.05277919826008
   PubMed Web of Science ®Google Scholar
• Fedorko M, Pacik D, Wasserbauer R, et al. MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers. Int J Biol Markers. 2016;31(1):e26–37. doi:10.5301/jbm.500017426481440
   PubMed Web of Science ®Google Scholar
• Neal CS, Michael MZ, Rawlings LH, et al. The VHL-dependent regulation of microRNAs in renal cancer. BMC Med. 2010;8(1):64. doi:10.1186/1741-7015-8-6420964835
   PubMed Web of Science ®Google Scholar
• Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001;61(17):6394–6399.11522632
   PubMed Web of Science ®Google Scholar
• Gattolliat CH, Couve S, Meurice G, et al. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. Int J Oncol. 2018;53(4):1455–1468. doi:10.3892/ijo.2018.449030066860
   PubMed Web of Science ®Google Scholar
• Hell MP, Thoma CR, Fankhauser N, et al. miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation. Cancer Res. 2014;74(9):2432–2443. doi:10.1158/0008-5472.CAN-13-204124491803
   PubMed Web of Science ®Google Scholar
• Mathew LK, Lee SS, Skuli N, et al. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2alpha activity. Cancer Discov. 2014;4(1):53–60. doi:10.1158/2159-8290.CD-13-029124189146
   PubMed Web of Science ®Google Scholar
• Wu TK, Wei CW, Pan YR, et al. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1alpha axis signals. Sci Rep. 2019;9(1):3207. doi:10.1038/s41598-019-39646-930824757
   PubMed Web of Science ®Google Scholar
• Liu W, Chen H, Wong N, et al. Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma. Cancer Lett. 2017;394:65–75. doi:10.1016/j.canlet.2017.02.02528257806
   PubMed Web of Science ®Google Scholar
• Ma X, Shen D, Li H, et al. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma. Urol Oncol. 2015;33(4):169 e161–111. doi:10.1016/j.urolonc.2015.01.00325700976
   PubMed Web of Science ®Google Scholar
• Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991–5004. doi:10.1200/JCO.2004.05.06115611513
   PubMed Web of Science ®Google Scholar
• Solomon D, Schwartz A. Renal pathology in von Hippel-Lindau disease. Hum Pathol. 1988;19(9):1072–1079. doi:10.1016/s0046-8177(88)80089-33417291
   PubMed Web of Science ®Google Scholar
• Heitzer E, Haque IS, Roberts CES, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71–88. doi:10.1038/s41576-018-0071-530410101
   PubMed Web of Science ®Google Scholar
• Wang X, Wang T, Chen C, et al. Serum exosomal miR-210 as a potential biomarker for clear cell renal cell carcinoma. J Cell Biochem. 2018. doi:10.1002/jcb.27347
   Web of Science ®Google Scholar
• von Brandenstein M, Pandarakalam JJ, Kroon L, et al. MicroRNA 15a, inversely correlated to PKCalpha, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol. 2012;180(5):1787–1797. doi:10.1016/j.ajpath.2012.01.01422429968
   PubMed Web of Science ®Google Scholar
• Shinden Y, Akiyoshi S, Ueo H, et al. Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases. Anticancer Res. 2015;35(1):123–127.25550542
   PubMed Web of Science ®Google Scholar
• Zhu K, He Y, Xia C, et al. MicroRNA-15a inhibits proliferation and induces apoptosis in CNE1 nasopharyngeal carcinoma cells. Oncol Res. 2016;24(3):145–151. doi:10.3727/096504016X1461196314229027458095
   PubMed Web of Science ®Google Scholar
• Li G, Zhao A, Peoch M, et al. Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma. Urol Oncol. 2017;35(5):294–299. doi:10.1016/j.urolonc.2016.12.00728089386
   PubMed Web of Science ®Google Scholar
• Petrozza V, Pastore AL, Palleschi G, et al. Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma. Oncotarget. 2017;8(41):69551–69558. doi:10.18632/oncotarget.1844929050224
   PubMedGoogle Scholar
• Petrozza V, Costantini M, Tito C, et al. Emerging role of secreted miR-210-3p as potential biomarker for clear cell renal cell carcinoma metastasis. Cancer Biomark. 2020;27(2):181–188. doi:10.3233/CBM-19024231771042
   PubMed Web of Science ®Google Scholar
• Di Meo A, Brown MD, Finelli A, et al. Prognostic urinary miRNAs for the assessment of small renal masses. Clin Biochem. 2020;75:15–22. doi:10.1016/j.clinbiochem.2019.10.002.31672647
   PubMed Web of Science ®Google Scholar
• Wang C, Cai L, Liu J, et al. MicroRNA-30a-5p inhibits the growth of renal cell carcinoma by modulating GRP78 expression. Cell Physiol Biochem. 2017;43(6):2405–2419. doi:10.1159/00048439429073630
   PubMedGoogle Scholar
• Zheng B, Zhu H, Gu D, et al. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib. Biochem Biophys Res Commun. 2015;459(2):234–239. doi:10.1016/j.bbrc.2015.02.08425712526
   PubMed Web of Science ®Google Scholar
• Outeiro-Pinho G, Barros-Silva D, Aznar E, et al. MicroRNA-30a-5p(me): a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples. J Exp Clin Cancer Res. 2020;39(1):98. doi:10.1186/s13046-020-01600-332487203
   PubMed Web of Science ®Google Scholar
• Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006. doi:10.1038/cr.2008.28218766170
   PubMed Web of Science ®Google Scholar
• Tusong H, Maolakuerban N, Guan J, et al. Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma. Cancer Biomark. 2017;18(1):79–85. doi:10.3233/CBM-16067627814278
   PubMed Web of Science ®Google Scholar
• Huang G, Li H, Wang J, et al. Combination of tumor suppressor miR-20b-5p, miR-30a-5p, and miR-196a-5p as a serum diagnostic panel for renal cell carcinoma. Pathol Res Pract. 2020;216(11):153152. doi:10.1016/j.prp.2020.15315232823234
   PubMed Web of Science ®Google Scholar
• Heinemann FG, Tolkach Y, Deng M, et al. Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clin Epigenetics. 2018;10(1):11. doi:10.1186/s13148-018-0444-929410711
   PubMed Web of Science ®Google Scholar
• Liu S, Deng X, Zhang J. Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma. Mol Med Rep. 2019;20(6):5075–5083. doi:10.3892/mmr.2019.1076231661117
   PubMed Web of Science ®Google Scholar
• Zhao L, Liu K, Pan X, et al. miR-625-3p promotes migration and invasion and reduces apoptosis of clear cell renal cell carcinoma. Am J Transl Res. 2019;11(10):6475–6486.31737199
   PubMed Web of Science ®Google Scholar
• Pigati L, Yaddanapudi SCS, Iyengar R, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One. 2010;5(10):e13515. doi:10.1371/journal.pone.001351520976003
   PubMed Web of Science ®Google Scholar
• Wang K, Yuan Y, Cho JH, et al. Comparing the MicroRNA spectrum between serum and plasma. PLoS One. 2012;7(7):e41561. doi:10.1371/journal.pone.004156122859996
   PubMed Web of Science ®Google Scholar
• Lou N, Ruan AM, Qiu B, et al. miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma. Urol Oncol. 2017;35(1):36 e37–36 e14. doi:10.1016/j.urolonc.2016.07.012
   Web of Science ®Google Scholar
• Chanudet E, Wozniak MB, Bouaoun L, et al. Large-scale genome-wide screening of circulating microRNAs in clear cell renal cell carcinoma reveals specific signatures in late-stage disease. Int J Cancer. 2017;141(9):1730–1740. doi:10.1002/ijc.3084528639257
   PubMed Web of Science ®Google Scholar
• Wang XG, Zhu YW, Wang T, et al. MiR-483-5p downregulation contributed to cell proliferation, metastasis, and inflammation of clear cell renal cell carcinoma. Kaohsiung J Med Sci. 2020. doi:10.1002/kjm2.12320
   Web of Science ®Google Scholar
• Lucca I, de Martino M, Hofbauer SL, et al. Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. World J Urol. 2015;33(12):2045–2052. doi:10.1007/s00345-015-1559-725894368
   PubMed Web of Science ®Google Scholar
• Ohno Y, Nakashima J, Ohori M, et al. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol. 2012;187(2):411–417. doi:10.1016/j.juro.2011.10.02622177153
   PubMed Web of Science ®Google Scholar
• Sonoda Y, Warita M, Suzuki T, et al. Proteolipid protein 2 is associated with melanoma metastasis. Oncol Rep. 2010;23(2):371–376.20043097
   PubMed Web of Science ®Google Scholar
• Xiao W, Wang C, Chen K, et al. MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2. EBioMedicine. 2020;51:102622. doi:10.1016/j.ebiom.2019.10262231901870
   PubMed Web of Science ®Google Scholar
• Chen X, Lou N, Ruan A, et al. miR-224/miR-141 ratio as a novel diagnostic biomarker in renal cell carcinoma. Oncol Lett. 2018;16(2):1666–1674. doi:10.3892/ol.2018.887430008851
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659. doi:10.1038/ncb159617486113
   PubMed Web of Science ®Google Scholar
• Honegger A, Schilling D, Bastian S, et al. Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells. PLoS Pathog. 2015;11(3):e1004712. doi:10.1371/journal.ppat.100471225760330
   PubMed Web of Science ®Google Scholar
• Kahlert C, Melo SA, Protopopov A, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem. 2014;289(7):3869–3875. doi:10.1074/jbc.C113.53226724398677
   PubMed Web of Science ®Google Scholar
• Bao L, You B, Shi S, et al. Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10. Oncogene. 2018;37(21):2873–2889. doi:10.1038/s41388-018-0183-629520105
   PubMed Web of Science ®Google Scholar
• Keller S, Sanderson MP, Stoeck A, et al. Exosomes: from biogenesis and secretion to biological function. Immunol Lett. 2006;107(2):102–108. doi:10.1016/j.imlet.2006.09.00517067686
   PubMed Web of Science ®Google Scholar
• Rana S, Malinowska K, Zoller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 2013;15(3):281–295. doi:10.1593/neo.12201023479506
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang S, Yao J, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015;527(7576):100–104. doi:10.1038/nature1537626479035
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng Q, Bao C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25(8):981–984. doi:10.1038/cr.2015.8226138677
   PubMed Web of Science ®Google Scholar
• Butz H, Nofech-Mozes R, Ding Q, et al. Exosomal MicroRNAs are diagnostic biomarkers and can mediate cell-cell communication in renal cell carcinoma. Eur Urol Focus. 2016;2(2):210–218. doi:10.1016/j.euf.2015.11.00628723537
   PubMedGoogle Scholar
• Yang C, Robbins PD. The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol. 2011;2011:842849. doi:10.1155/2011/84284922190973
   PubMed Web of Science ®Google Scholar
• Zhang W, Ni M, Su Y, et al. MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur Urol Focus. 2018;4(3):412–419. doi:10.1016/j.euf.2016.09.00728753793
   PubMedGoogle Scholar
• Folkerts H, Wierenga AT, van den Heuvel FA, et al. Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protective against venetoclax-induced apoptosis. Cell Death Dis. 2019;10(6):421. doi:10.1038/s41419-019-1648-431142733
   PubMed Web of Science ®Google Scholar
• Ying Q, Liang L, Guo W, et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology. 2011;54(6):2064–2075. doi:10.1002/hep.2461422144109
   PubMed Web of Science ®Google Scholar
• Crentsil VC, Liu H, Sellitti DF. Comparison of exosomal microRNAs secreted by 786-O clear cell renal carcinoma cells and HK-2 proximal tubule-derived cells in culture identifies microRNA-205 as a potential biomarker of clear cell renal carcinoma. Oncol Lett. 2018;16(1):1285–1290. doi:10.3892/ol.2018.875130061948
   PubMed Web of Science ®Google Scholar
• Xu XW, Li S, Yin F, et al. Expression of miR-205 in renal cell carcinoma and its association with clinicopathological features and prognosis. Eur Rev Med Pharmacol Sci. 2018;22(3):662–670. doi:10.26355/eurrev_201802_1429129461593
   PubMed Web of Science ®Google Scholar
• Koren E, Fuchs Y. The bad seed: cancer stem cells in tumor development and resistance. Drug Resist Updat. 2016;28:1–12. doi:10.1016/j.drup.2016.06.00627620951
   PubMed Web of Science ®Google Scholar
• Vahidian F, Mohammadi H, Ali-Hasanzadeh M, et al. MicroRNAs and breast cancer stem cells: potential role in breast cancer therapy. J Cell Physiol. 2019;234(4):3294–3306. doi:10.1002/jcp.2724630362508
   PubMed Web of Science ®Google Scholar
• Wang L, Yang G, Zhao D, et al. CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote MiR-19b-3p. Mol Cancer. 2019;18(1):86. doi:10.1186/s12943-019-0997-z30975145
   PubMed Web of Science ®Google Scholar
• Song S, Long M, Yu G, et al. Urinary exosome miR-30c-5p as a biomarker of clear cell renal cell carcinoma that inhibits progression by targeting HSPA5. J Cell Mol Med. 2019;23(10):6755–6765. doi:10.1111/jcmm.1455331342628
   PubMed Web of Science ®Google Scholar
• Yang GH, Li S, Pestka JJ. Down-regulation of the endoplasmic reticulum chaperone GRP78/BiP by vomitoxin (deoxynivalenol). Toxicol Appl Pharmacol. 2000;162(3):207–217. doi:10.1006/taap.1999.884210652249
   PubMed Web of Science ®Google Scholar
• Xiao CT, Lai WJ, Zhu WA, et al. MicroRNA derived from circulating exosomes as noninvasive biomarkers for diagnosing renal cell carcinoma. Onco Targets Ther. 2020;13:10765–10774. doi:10.2147/OTT.S27160633122915
   PubMed Web of Science ®Google Scholar
• Sun B, Zhang J, Liu M, et al. Alkannin inhibits proliferation, migration and invasion of hepatocellular carcinoma cells via regulation of miR-92a. Biomed Pharmacother. 2019;114:108782. doi:10.1016/j.biopha.2019.10878230909147
   PubMed Web of Science ®Google Scholar
• Si H, Sun X, Chen Y, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. 2013;139(2):223–229. doi:10.1007/s00432-012-1315-y23052693
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu Z. Serum miR-92a-1 is a novel diagnostic biomarker for colorectal cancer. J Cell Mol Med. 2020;24(15):8363–8367. doi:10.1111/jcmm.1528232562465
   PubMed Web of Science ®Google Scholar
• Cui Y, Yang J, Bai Y, et al. miR-424-5p regulates cell proliferation and migration of esophageal squamous cell carcinoma by targeting SIRT4. J Cancer. 2020;11(21):6337–6347. doi:10.7150/jca.5058733033517
   PubMed Web of Science ®Google Scholar
• Liu X, Fu Y, Zhang G, et al. miR-424-5p promotes anoikis resistance and lung metastasis by inactivating hippo signaling in thyroid cancer. Mol Ther Oncol. 2019;15:248–260. doi:10.1016/j.omto.2019.10.008
   PubMed Web of Science ®Google Scholar
• Jin L, Li Y, Liu J, et al. Tumor suppressor miR-149-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma. Mol Med Rep. 2016;13(6):5386–5392. doi:10.3892/mmr.2016.520527121091
   PubMed Web of Science ®Google Scholar
• Guo P, Sheng M, Liu H, et al. Effects of miR-218-1-3p and miR-149 on proliferation and apoptosis of non-small cell lung cancer cells. Oncol Lett. 2020;20(4):96. doi:10.3892/ol.2020.1195732831915
   PubMed Web of Science ®Google Scholar
• Youssef YM, White NM, Grigull J, et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol. 2011;59(5):721–730. doi:10.1016/j.eururo.2011.01.00421272993
   PubMed Web of Science ®Google Scholar
• Qi Y, Wang L, Wang K, et al. New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies. Biomed Pharmacother. 2019;111:821–834. doi:10.1016/j.biopha.2018.12.09930616081
   PubMed Web of Science ®Google Scholar
• Nie W, Ni D, Ma X, et al. miR122 promotes proliferation and invasion of clear cell renal cell carcinoma by suppressing Forkhead box O3. Int J Oncol. 2019;54(2):559–571. doi:10.3892/ijo.2018.463630483771
   PubMed Web of Science ®Google Scholar
• Lin C, Li Z, Chen P, et al. Oncogene miR-154-5p regulates cellular function and acts as a molecular marker with poor prognosis in renal cell carcinoma. Life Sci. 2018;209:481–489. doi:10.1016/j.lfs.2018.08.04430138594
   PubMed Web of Science ®Google Scholar
• Zhang J, Ye Y, Chang DW, et al. Global and targeted miRNA expression profiling in clear cell renal cell carcinoma tissues potentially links miR-155-5p and miR-210-3p to both tumorigenesis and recurrence. Am J Pathol. 2018;188(11):2487–2496. doi:10.1016/j.ajpath.2018.07.02630201497
   PubMed Web of Science ®Google Scholar
• Ralla B, Busch J, Florcken A, et al. miR-9-5p in nephrectomy specimens is a potential predictor of primary resistance to first-line treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Cancers (Basel). 2018;10(9):321. doi:10.3390/cancers10090321
   PubMed Web of Science ®Google Scholar
• Garrigos C, Molina-Pinelo S, Melendez R, et al. MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer. Urol Oncol. 2020;38(7):640 e623–640 e629. doi:10.1016/j.urolonc.2020.01.012
   Web of Science ®Google Scholar
• Incorvaia L, Fanale D, Badalamenti G, et al. A “lymphocyte MicroRNA signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: pointing towards epigenetic reprogramming. Cancers (Basel). 2020;12(11):3396. doi:10.3390/cancers12113396
   PubMed Web of Science ®Google Scholar
• Qu F, Ye J, Pan X, et al. MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma. J Drug Target. 2019;27(1):67–74. doi:10.1080/1061186X.2018.147975530183478
   PubMed Web of Science ®Google Scholar
• Tito C, De Falco E, Rosa P, et al. Circulating microRNAs from the molecular mechanisms to clinical biomarkers: a focus on the clear cell renal cell carcinoma. Genes (Basel). 2021;12(8):1154. doi:10.3390/genes1208115434440329
   PubMed Web of Science ®Google Scholar
• Szabo Z, Szegedi K, Gombos K, et al. Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC. Urol Oncol. 2016;34(12):533 e521–533 e527. doi:10.1016/j.urolonc.2016.06.011
   Web of Science ®Google Scholar
• Liu F, Chen N, Xiao R, et al. miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8. Biochem Biophys Res Commun. 2016;480(1):87–93. doi:10.1016/j.bbrc.2016.10.00427717821
   PubMed Web of Science ®Google Scholar
• Liep J, Kilic E, Meyer HA, et al. Cooperative effect of miR-141-3p and miR-145-5p in the regulation of targets in clear cell renal cell carcinoma. PLoS One. 2016;11(6):e0157801. doi:10.1371/journal.pone.015780127336447
   PubMed Web of Science ®Google Scholar
• Chen B, Duan L, Yin G, et al. Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells—Cdc2 activity is up-regulated by targeting WEE1. Clinics (Sao Paulo). 2013;68(6):825–833. doi:10.6061/clinics/2013(06)1723778472
   PubMed Web of Science ®Google Scholar
• He Y, Liu J, Wang Y, et al. Role of miR-486-5p in regulating renal cell carcinoma cell proliferation and apoptosis via TGF-beta-activated kinase 1. J Cell Biochem. 2019;120(3):2954–2963. doi:10.1002/jcb.2690030537206
   PubMed Web of Science ®Google Scholar
• Yao D, Xia S, Jin C, et al. Feedback activation of GATA1/miR-885-5p/PLIN3 pathway decreases sunitinib sensitivity in clear cell renal cell carcinoma. Cell Cycle. 2020;19(17):2195–2206. doi:10.1080/15384101.2020.180118932783497
   PubMed Web of Science ®Google Scholar